322 related articles for article (PubMed ID: 36358874)
1. Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer.
Sun X; Liu K; Lu S; He W; Du Z
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358874
[TBL] [Abstract][Full Text] [Related]
2. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Treatments: Updates and New Challenges.
Burguin A; Diorio C; Durocher F
J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442452
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.
Saha T; Lukong KE
Front Oncol; 2022; 12():856974. PubMed ID: 35392236
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
Ayoub NM; Al-Shami KM; Yaghan RJ
Breast Cancer (Dove Med Press); 2019; 11():53-69. PubMed ID: 30697064
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer: an up-to-date review and future perspectives.
Hong R; Xu B
Cancer Commun (Lond); 2022 Oct; 42(10):913-936. PubMed ID: 36074908
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapy and immunotherapy for hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer (Review).
Song Y; He L; Wang Y; Wu Q; Huang W
Oncol Rep; 2020 Jul; 44(1):3-13. PubMed ID: 32319666
[TBL] [Abstract][Full Text] [Related]
8. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
9. Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy.
Bou-Dargham MJ; Draughon S; Cantrell V; Khamis ZI; Sang QA
J Cancer; 2021; 12(23):6949-6963. PubMed ID: 34729098
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.
Ferrando-Díez A; Felip E; Pous A; Bergamino Sirven M; Margelí M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884366
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
12. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
13. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer.
Harbeck N; Penault-Llorca F; Cortes J; Gnant M; Houssami N; Poortmans P; Ruddy K; Tsang J; Cardoso F
Nat Rev Dis Primers; 2019 Sep; 5(1):66. PubMed ID: 31548545
[TBL] [Abstract][Full Text] [Related]
16. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options.
Singh K; Yadav D; Jain M; Singh PK; Jin JO
Endocr Metab Immune Disord Drug Targets; 2022; 22(2):212-224. PubMed ID: 33902424
[TBL] [Abstract][Full Text] [Related]
18. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
19. New and Emerging Targeted Therapies for Advanced Breast Cancer.
Lau KH; Tan AM; Shi Y
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216405
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives.
Agostinetto E; Montemurro F; Puglisi F; Criscitiello C; Bianchini G; Del Mastro L; Introna M; Tondini C; Santoro A; Zambelli A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
